CellTrans

Executive Summary

CellTrans is a clinical-stage biotechnology company based in Chicago, Illinois, that has successfully developed and obtained FDA approval for LANTIDRA, a human pancreatic islet cell therapy for the treatment of Type 1 diabetes. Founded in 2009, the company combines its proprietary cell therapy platform with specialized contract research and manufacturing services for autologous and allogeneic cell therapies. LANTIDRA represents a breakthrough in diabetes care, offering a cellular replacement approach that can restore insulin independence in eligible patients. With its first product now approved, CellTrans is transitioning from a development-stage company to a commercial entity, leveraging its manufacturing expertise to scale production and serve both its own pipeline and external clients. The company's dual revenue model—product sales and service contracts—provides a diversified foundation for growth.

Upcoming Catalysts (preview)

• Q3 2026Commercial Launch Execution and Reimbursement Milestones for LANTIDRA85% success
• 2026Strategic Partnership for Sales and Distribution Outside the US60% success
• H2 2026Expansion of Manufacturing Capacity for Islet Cell Production70% success